MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/srep19423

Медицинская библиотека · Scientific reports · 2016

Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.

Wang Yongfeng, Wang Long, Guan Shan, Cao Wenming, Wang Hao, Chen Zhenghu, Zhao Yanling, Yu Yang, Zhang Huiyuan, Pang Jonathan C, Huang Sophia L, Akiyama Yo, Yang Yifan, Sun Wenjing, Xu Xin, Shi Yan, Zhang Hong, Kim Eugene S, Muscal Jodi A, Lu Fengmin, Yang Jianhua

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

ALK receptor tyrosine kinase has been shown to be a therapeutic target in neuroblastoma. Germline ALK activating mutations are responsible for the majority of hereditary neuroblastoma and somatic ALK activating mutations are also frequently observed in sporadic cases of advanced NB. Crizotinib, a first-line therapy in the treatment of advanced non-small cell lung cancer (NSCLC) harboring ALK rearrangements, demonstrates striking efficacy against ALK-rearranged NB. However, crizotinib fails to effectively inhibit the activity of ALK when activating mutations are present within its kinase domain, as with the F1174L mutation. Here we show that a new ALK inhibitor AZD3463 effectively suppressed the proliferation of NB cell lines with wild type ALK (WT) as well as ALK activating mutations (F1174L and D1091N) by blocking the ALK-mediated PI3K/AKT/mTOR pathway and ultimately induced apoptosis and autophagy. In addition, AZD3463 enhanced the cytotoxic effects of doxorubicin on NB cells. AZD3463 also exhibited significant therapeutic efficacy on the growth of the NB tumors with WT and F1174L activating mutation ALK in orthotopic xenograft mouse models. These results indicate that AZD3463 is a promising therapeutic agent in the treatment of NB.

Для цитирования: Wang Yongfeng, Wang Long, Guan Shan, Cao Wenming, Wang Hao, Chen Zhenghu, Zhao Yanling, Yu Yang, Zhang Huiyuan, Pang Jonathan C, Huang Sophia L, Akiyama Yo, Yang Yifan, Sun Wenjing, Xu Xin, Shi Yan, Zhang Hong, Kim Eugene S, Muscal Jodi A, Lu Fengmin, Yang Jianhua. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.. Scientific reports. 2016. DOI: 10.1038/srep19423.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.